Purchase Order 75N92B26P00004
- Not listed
- Becton, Dickinson and Company (BD), operating through its BDB Division as BD Biosciences, received a $22,500 firm fixed-price contract award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMSD) on December 19, 2019. This contract call was issued under a Blanket Purchase Agreement (BPA) with an ultimate completion date of December 31, 2019, and was awarded without a small business set-aside designation. The work is to be performed in Bethesda, Maryland, where...
- Becton, Dickinson and Company (BD), through its BDB Division operating as BD Biosciences, received a contract award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMSD) for $8,217.50. This Blanket Purchase Agreement (BPA) call was awarded on December 18, 2015, with a completion date of December 31, 2015, utilizing firm fixed-price pricing. The contract involved no small business set-aside designation and was performed in Bethesda, Maryland. As a child entity...
- Becton, Dickinson and Company, through its BD Biosciences division, was awarded a $22,613.40 firm fixed-price contract call under a Blanket Purchase Agreement by the National Institute of Arthritis and Musculoskeletal and Skin Diseases for the provision of scientific instruments and related services. The contract, awarded on March 11, 2020, with an ultimate completion date of August 31, 2020, will support the institute's research operations at its Bethesda, Maryland facility. No small business...
- Becton, Dickinson and Company (BD), through its BDB Division operating as BD Biosciences, received a $5,258.95 firm fixed price Blanket Purchase Agreement (BPA) call award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases on June 14, 2018, with an ultimate completion date of July 31, 2018. The contract was awarded without a set-aside designation and will be performed in Bethesda, Maryland. As a global medical technology manufacturer specializing in flow cytometry...
- Becton, Dickinson and Company (BD), operating through its BDB Division as BD Biosciences, was awarded a Blanket Purchase Agreement (BPA) call contract valued at $14,942.85 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMSD), a component of the National Institutes of Health. The contract, awarded on August 24, 2012, with an ultimate completion date of March 31, 2013, was issued on a firm fixed-price basis without a small business set-aside designation....
- Becton, Dickinson and Company (BD), through its BDB Division operating as BD Biosciences, received a $21,587.40 Blanket Purchase Agreement (BPA) call from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) with a firm fixed price structure. The contract was awarded on February 16, 2017, with an ultimate completion date of March 31, 2018, and designated the place of performance as Bethesda, Maryland. This award was processed without a small business set-aside and...
- Becton, Dickinson and Company (BD), through its BDB Division operating as BD Biosciences, was awarded a $17,172 firm fixed price Blanket Purchase Agreement (BPA) call by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) on November 7, 2019, with an ultimate completion date of November 30, 2019. This contract, which utilized no small business set-aside, represents a call against an existing BPA vehicle and is to be performed at the agency's location in Bethesda,...
- Becton, Dickinson and Company (BD), through its BDB Division operating as BD Biosciences, received a Firm Fixed Price Blanket Purchase Agreement (BPA) call valued at $21,587.40 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a component of the National Institutes of Health. The contract was awarded on February 8, 2019, with an ultimate completion date of July 31, 2019, for performance at the NIH campus in Bethesda, Maryland. No small business set-aside was...
- Becton, Dickinson and Company, through its BD Biosciences division, received a $16,169.52 firm fixed price Blanket Purchase Agreement (BPA) call award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) on November 7, 2019, with an ultimate completion date of November 30, 2019. The contract involves the procurement of service and maintenance for an LSR II Preconfligurated laser system with violet capabilities (Customer Material #648068, Serial #H06800002)....
- Becton, Dickinson and Company (BD), operating through its BDB Division as BD Biosciences, was awarded a contract by the National Institute of Arthritis and Musculoskeletal and Skin Diseases for custom reagents valued at $7,628.00. This Blanket Purchase Agreement (BPA) call was awarded on May 3, 2018, with an ultimate completion date of July 31, 2018, using firm fixed price terms and no small business set-aside. The contract represents procurement of specialized research reagents to support the...
Becton, Dickinson and Company (BD), through its BDB Division operating as BD Biosciences, was awarded a $22,107.60 firm fixed-price purchase order by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMSD) on December 23, 2025, with an ultimate completion date of December 22, 2026. The contract was awarded without a set-aside designation and will be performed in San Jose, California. As a global medical technology manufacturer specializing in flow cytometry systems, cell imaging technologies, and related laboratory instrumentation, BD will provide products or services supporting the institute's research and clinical capabilities in arthritis, musculoskeletal, and skin disease research. This award reflects BD's established position as a key federal supplier of advanced biomedical research technologies to National Institutes of Health components and other government agencies. The company maintains multiple indefinite delivery vehicles and blanket purchase agreements across federal agencies, including the Department of Veterans Affairs and NIH Clinical Center, demonstrating its strategic importance in supplying sophisticated flow cytometry instruments, reagents, and technical support services. The relatively modest ceiling value of this purchase order suggests a targeted procurement, likely for specific reagents, consumables, or maintenance services in support of ongoing research initiatives at NIAMSD.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $22.1k | 12/23/25 |